Search hospitals > New York > Auburn
Hematology Oncology Associates of Central New York-Auburn
Claim this profileAuburn, New York 13021
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
50 reported clinical trials
2 medical researchers
Summary
Hematology Oncology Associates of Central New York-Auburn is a medical facility located in Auburn, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Hematology Oncology Associates of Central New York-Auburn is involved with conducting 50 clinical trials across 105 conditions. There are 2 research doctors associated with this hospital, such as Jeffrey J. Kirshner and Steven M. Duffy.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 positive
PR positive
Top PIs
Jeffrey J. KirshnerHematology Oncology Associates of Central New York-East Syracuse4 years of reported clinical research
Studies Cancer
Studies Lung Cancer
26 reported clinical trials
50 drugs studied
Steven M. DuffyHematology Oncology Associates of Central New York-East Syracuse4 years of reported clinical research
Studies Cancer
Studies Lung Cancer
18 reported clinical trials
38 drugs studied
Clinical Trials running at Hematology Oncology Associates of Central New York-Auburn
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Multiple Myeloma
Cancer
Squamous Cell Carcinoma
ALK Gene Rearrangement
Lymphoma
Cognitive Impairment
Plasma Cell Neoplasms
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Cognitive Training
for Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Hematology Oncology Associates of Central New York-Auburn?
Hematology Oncology Associates of Central New York-Auburn is a medical facility located in Auburn, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Hematology Oncology Associates of Central New York-Auburn is involved with conducting 50 clinical trials across 105 conditions. There are 2 research doctors associated with this hospital, such as Jeffrey J. Kirshner and Steven M. Duffy.